Everest Organics receives one USFDA observation for Aroor plant

06 Mar 2017 Evaluate

Everest Organics’ Aroor plant was inspected by the United States Food and Drug Administration (USFDA) from February 27, 2017 to March 3, 2017 and the regulator has made one observation. The company believes that this is of minor nature and corrective & preventive action for this observation will be presented to the regulator shortly.

Everest Organics is engaged in the business of bulk drugs and active pharmaceutical ingredients (APIs). It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen and Benzimadizole.

Everest Organics Share Price

482.60 0.00 (0.00%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1772.55
Dr. Reddys Lab 1269.10
Cipla 1491.50
Zydus Lifesciences 914.75
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×